SHANGHAI, March 27, 2020 /PRNewswire/ -- China's leading online pharmaceutical network
and healthcare service provider is partnering with the Wenjiang
People's Hospital in Chengdu to
build an online cancer diagnosis and treatment platform for rare
tumors using imported drugs. The new rare tumor platform will be
linked with the national network of online diagnosis and treatment
services operated by 111, Inc. (NASDAQ: YI) ("111"), which is
creating a healthcare ecology around medical consultations as well
as prescription drug supply through its partnerships with 235,000
out of China's 450,000
pharmacies.
The new Internet hospital based in the Wenjiang district of
Chengdu in Sichuan Province will leverage the tumor
diagnosis and treatment platform under the Alliance Healthcare
Services (AIQ) - Wenjiang International Oncology Institute
affiliated with Wenjiang People's
Hospital, as well as provide services similar to 111's growing
network of Internet hospitals. Services will include online
consultation, follow-up consultations for chronic disease patients,
safe and traceable e-prescriptions, and medication sales and
delivery. It will also feature a prescription information system
with prescription traceability throughout the process from
consultation to delivery of prescription drug refills, enabled by
111's data analytics and Customer Relationship Management (CRM)
technology.
Rich, integrated healthcare resources create favorable
industry environment in Wenjiang
Mr. Tong Liu, Senior Vice President and Chief Public Relations
Officer of 111, commented, "Wenjiang is a leading healthcare
industry cluster with integrated expertise and resources in
'medical science, medical products, and medical care + artificial
intelligence/big data analytics'. This was the key factor in our
decision to set up operations here. We are very excited to be
establishing a foothold in Wenjiang. As the first Internet
pharmaceutical and healthcare platform in Wenjiang, we are
confident that we will serve the local government as a strong
private sector partner. We will leverage our advantages in Internet
technology and supply chain management further empower the local
healthcare industry in Wenjiang."
Wenjiang has been designed to serve as a demonstration model for
high technology healthcare, with a development plan centered on the
integration of "medical science, medical products, and medical care
+ artificial intelligence/big data analytics". Its three industrial
parks, Chengdu Medical City (CMC), Chengdu Modern Service
Industrial Cluster, and Chengdu Modern Agricultural High-Tech
Industrial Park, are under construction as part of the China (Sichuan) Pilot Free Trade Zone and a business
environment demonstration zone. Newly included in the central urban
district of Chengdu, Wenjiang has
ranked among the Top 100 Chinese Districts for Comprehensive
Strength for eight consecutive years.
The Wenjiang health cluster includes more than 300 biomedical
enterprises, 30 medical care institutions, and 5 high-end
healthcare institutions and nursing homes. Within the cluster,
revenue of the pharmaceutical and healthcare enterprises in Chengdu
Medical City has increased by 25% annually over the past three
years
A Wenjiang Investment Promotion Bureau Administration official
commented: "As China deepens its medical sector reforms and
promotes the 'Internet +
healthcare' concept, we are excited
to welcome leading Internet pharmaceutical and healthcare companies
like 111 to set up operations in our district and join forces with
local enterprises. We look forward to seeing more
technology-powered healthcare collaborations in Wenjiang that will
build our advantages as a national and regional healthcare hub."
An alliance to improve resource allocation of imported
anti-tumor drugs
111's Chengdu Internet hospital and Wenjiang People's Hospital will leverage the
tumor diagnosis and treatment platform under the Alliance Health
Care Services (AIQ) - Wenjiang International Oncology Institute
affiliated with Wenjiang People's
Hospital to improve resource allocation of imported anti-tumor
drugs.
A Wenjiang People's Hospital
supervisor, added, "With 111's support, we will be able to take
better advantage of cloud-based solutions and smart supply chain
management to supply international anti-tumor drugs. Through this
partnership, we are looking to expand our service coverage for our
rare tumor program beyond the southwestern region to reach patients
nationwide."
Mr. Liu added, "Our Internet hospital business is playing a
pivotal role in 111's development in central and western
China. Our strategy is to leverage
information technology to enable patients nationwide to access
high-quality medical resources in eastern China and other centers of excellence, such as
the healthtech cluster in Wenjiang. The partnership with the
Wenjiang People's Hospital deepens our diagnostic resources and
strengthens our industrial value chain based on closed-loop
services from diagnosis to medication and payment."
Safe Harbor Statement
This press release contains forward-looking statements. These
statements constitute "forward-looking" statements within the
meaning of Section 21E of the Securities Exchange Act of 1934, as
amended, and as defined in the U.S. Private Securities Litigation
Reform Act of 1995. These forward-looking statements can be
identified by terminology such as "will," "expects," "anticipates,"
"future," "intends," "plans," "believes," "estimates," "target,"
"confident" and similar statements. Among other things, the
Business Outlook and quotations from management in this
announcement, as well as 111's strategic and operational plans,
contain forward-looking statements. 111 may also make written or
oral forward-looking statements in its periodic reports to the U.S.
Securities and Exchange Commission, in its annual report to
shareholders, in press releases and other written materials and in
oral statements made by its officers, directors or employees to
third parties. Such statements are based upon management's current
expectations and current market and operating conditions and relate
to events that involve known or unknown risks, uncertainties and
other factors, all of which are difficult to predict and many of
which are beyond the Company's control. Forward-looking statements
involve inherent risks, uncertainties and other factors that could
cause actual results to differ materially from those contained in
any such statements. Potential risks and uncertainties include, but
are not limited to, uncertainties as to the Company's ability
comply with extensive and evolving regulatory requirements, its
ability to compete effectively in the evolving PRC general health
and wellness market, its ability to manage the growth of its
business and expansion plans, its ability to achieve or maintain
profitability in the future, its ability to control the risks
associated with its pharmaceutical retail and wholesale businesses,
and the Company's ability to meet the standards necessary to
maintain listing of its ADSs on the Nasdaq Global Market, including
its ability to cure any non-compliance with Nasdaq's continued
listing criteria. Further information regarding these and other
risks, uncertainties or factors is included in the Company's
filings with the U.S. Securities and Exchange Commission. All
information provided in this press release is as of the date of
this press release, and 111 does not undertake any obligation to
update any forward-looking statement as a result of new
information, future events or otherwise, except as required under
applicable law.
About 111, Inc.
111, Inc. (NASDAQ: YI) ("111" or the "Company") is a leading
integrated online and offline healthcare platform in China. The Company provides hundreds of
millions of consumers with better access to pharmaceutical products
and healthcare services directly through its online retail pharmacy
and indirectly through its offline pharmacy network. 111 also
offers online healthcare services through its internet hospital, 1
Clinic, which provides consumers with cost-effective and convenient
online consultation and electronic prescription services. In
addition to providing direct services to consumers through its
online retail pharmacy, 111 also enables offline pharmacies to
better serve their customers. The Company's online wholesale
pharmacy, 1 Drug Mall, serves as a one-stop shop for pharmacies to
source a vast selection of pharmaceutical products. The Company's
new retail platform, by integrating the front and back ends of the
pharmaceutical supply chain, has formed a smart supply chain, which
transforms the flow of pharmaceutical products to pharmacies and
modernizes how they serve their customers.
For more information on 111, please visit
http://ir.111.com.cn/.
For more information, please contact:
111, Inc.
IR Director
Ms. Monica Mu
E-mail: ir@111.com.cn
Christensen
In China
Mr. Christian Arnell
Phone: +86-10-5900-1548
E-mail: carnell@christensenir.com
In US
Ms. Linda Bergkamp
Phone: +1-480-614-3004
Email: lbergkamp@christensenir.com
View original
content:http://www.prnewswire.com/news-releases/111-and-wenjiang-peoples-hospital-to-build-online-cancer-diagnosis-and-treatment-platform-301030868.html
SOURCE 111, Inc.